{'fraction_non_alphanumeric': 0.015584415584415584, 'fraction_numerical': 0.0, 'mean_word_length': 5.4789915966386555, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapeutic galactose effect on metabolic dysfunction and cognition in sporadic rat model of Alzheimer's disease

Metabolic dysfunction in the brain is considered to be one of the main pathophysiological hallmarks of sporadic Alzheimer's disease (sAD). Galactose may serve as an alternative source of energy which could be of a therapeutic value for the cerebral glucose hypometabolism in sAD. Our previous research has shown that oral galactose might prevent cognitive deficit in a rat model of sAD. This study aims to explore whether chronic oral galactose treatment could have therapeutic effects on metabolic and cognitive deficit manifested already at the time of initiation of galactose treatment in intracerebroventricular streptozotocin (STZ-icv) - treated rats.